Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company’s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer.
As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.
For more information, visit www.cybrexa.com.
As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.
For more information, visit www.cybrexa.com.
Location: United States, Connecticut, New Haven
Employees: 11-50
Total raised: $44.4M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
| - | HighCape C... | highcape.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 11.03.2021 | Series B | $25M | - |
| 20.06.2019 | - | $13.4M | - |
| 18.06.2017 | Series B | $6M | - |
Mentions in press and media 13
| Date | Title | Description |
| 30.10.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 03.09.2024 | The Rise of Private Credit: SeaTown's Bold Move in Asia | In the ever-evolving landscape of finance, private credit is emerging as a formidable player. SeaTown Holdings International, a subsidiary of Temasek, has just closed its second private credit fund, SeaTown Private Credit Fund II (PCF II), ... |
| 29.08.2024 | Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS net profit reached RMB168.2 million, inc... |
| 11.03.2021 | Cybrexa Therapeutics Completes $25M Series B Financing | Cybrexa Therapeutics, a New Haven, CO-based oncology-focused biotechnology company, completed its $25m Series B financing. Backers included HighCape Capital and new investor Elm Street Ventures. The company intends to use the funds for plan... |
| 10.03.2021 | Cybrexa Therapeutics Closes $25 Million Series B Financing | -Proceeds will advance the company’s lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its ... |
| 10.03.2021 | Cybrexa Therapeutics Closes $25M in Series B | NEW HAVEN, CT, Cybrexa Therapeutics announced the completion of its $25 million Series B financing. >> Click here for more funding data on Cybrexa Therapeutics >> To export Cybrexa Therapeutics funding data to PDF and Excel,... |
| 20.06.2019 | Cybrexa Therapeutics Closes $13.4M in Series B1 Funding Round | NEW HAVEN, Conn., June 20, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced the completion of a $13.4 millio... |
| 20.06.2019 | Cybrexa Therapeutics Closes $13.4M in Series B1 Funding Round | NEW HAVEN, Conn., June 20, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced the completion of a $13.4 millio... |
| 20.06.2019 | Cybrexa Therapeutics Completes $13.4M in Series B1 Funding | Cybrexa Therapeutics, a New Haven, CT-based biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, completed a $13.4m Series B1 financing. Backers in the round, which brings total... |
| 19.06.2017 | Term Sheet — Monday, June 19 | A DECLARATION OF WAR Good morning. I’m back and still digesting Friday’s Amazon-Whole Foods news. (Nothing like a bombshell deal announcement on a summer Friday when I happen to be out of the office! Thanks again to Anne for filling in for ... |
Show more